Hla dr allophycocyanin apc clone g46 6

Manufactured by BD

Sourced in France, United States

HLA-DR-allophycocyanin (APC) (clone G46-6) is a fluorochrome-conjugated antibody that binds to the human leukocyte antigen (HLA)-DR protein. HLA-DR is a major histocompatibility complex (MHC) class II cell surface receptor expressed on antigen-presenting cells, such as B cells, monocytes, and dendritic cells. The APC fluorochrome is used to label the antibody, allowing for the detection and analysis of HLA-DR-positive cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Cd273 pe, by Thermo Fisher Scientific (1 mentions) Ifn γ fitc, by BD (1 mentions) Cd4 pb, by BioLegend (1 mentions) Cd8 pb, by BioLegend (1 mentions) Cd25 pe clone m a251, by BioLegend (1 mentions) Anti human foxp3 staining set apc clone 236a e7, by Thermo Fisher Scientific (1 mentions) Cd4 pe, by BD (1 mentions) Facscanto 2, by BD (1 mentions)

Close spelling variants of this product

HLA-DR (247 citations) HLA-DR-APC (31 citations) HLA-DR (clone G46-6, (12 citations)

2 protocols using hla dr allophycocyanin apc clone g46 6

Immunoblot and Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For the immunoblot analysis, following antibodies from Cell Signaling Technology (Ozyme, Saint Quentin Yvelines, France) were used: rabbit monoclonal antibodies (MAbs) to nonphospho (active) β-catenin (Ser33/37/Thr41) (clone D13A1), p-GSK-3β (Ser9) (clone D3A4), GAPDH (horseradish peroxidase conjugated [HRP], clone 14C10), β-actin (HRP conjugated, clone 13E5), and polyclonal antibodies to phospho (inactive) β-catenin (Ser33/37/Thr41).
For flow cytometry, the following fluorochrome-conjugated monoclonal antibodies were used: from BD Biosciences, HLA-DR-allophycocyanin (APC) (clone G46-6), CD8-PB (clone RPA-T8), IL-10-phycoerythrin (PE) (clone JES5-16E3), CD86-fluorescein isothiocyanate (FITC) (clone FUN-1), CD80-PE (clone L307.4), CD83-APC (clone HB15e), CD274-FITC (clone MIH1), CD252-PE (clone iK-1), CD275-PE (clone 2D3/B7-H2), CD273-PE (clone, MIH18), CD25-FITC (clone M-A251), CD127-BV421 (clone HIL-7RM21), CD279-APC (clone M1H4), IFN-γ-FITC (clone 4S.B3), IL-4-PE (clone MP4-25D2); from eBioscience: FoxP3-APC (clone 236A/E7), IL-2-APC (clone MQ1-17H12), IL-17A-PE (clone eBio64cap17), IL-17A-FITC (clone eBio64DEC1); from Beckman Coulter: CD40-PE (clone MAB89); from BioLegend: CD4-PerCP (clone SK3); and from Miltenyi Biotec, TNF-α-APC (clone cA2).
Cell viability was detected using the fixable viability dye eFluor 506 (eBioscience).

Karnam A., Bonam S.R., Rambabu N., Wong S.S., Aimanianda V, & Bayry J. (2021). Wnt-β-Catenin Signaling in Human Dendritic Cells Mediates Regulatory T-Cell Responses to Fungi via the PD-L1 Pathway. mBio, 12(6), e02824-21.

+ Open protocol

+ Expand

Comprehensive CD4+ T-Cell Phenotypic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For phenotypic analysis of CD4⁺-T, the following antibodies were used: CD4 PE (Clone RPA-T4), IFN-γ FITC (Clone B27), HLA-DR allophycocyanin (APC) (clone G46-6) (BD Pharmingen; BD Biosciences), CD3 PerCP (clone SK7) (Becton Dickinson, Franklin Lakes, NJ, USA); CD4 PB (Clone RPA-T4), CD8 PB (Clone RPA-T8), CD45RA PE/Cy7 (clone H100), CD25 PE (clone M-A251), CD127 PerCP/Cy5.5 (clone A019D5), CD185 APC/Cy7 (clone J252D4) (Biolegend); and CD54 Pacific Blue (clone HCD54), IL-17 efluor660 (eBioscience). Intracellular staining of FoxP3 was carried out with the anti-Human Foxp3 Staining Set APC (clone 236A/E7) (eBioscience). Flow cytometry was carried out on a FACS Canto II (BD Biosciences).

Lion J., Burbach M., Cross A., Poussin K., Taflin C., Kaveri S., Haziot A., Glotz D, & Mooney N. (2017). Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin. Frontiers in Immunology, 8, 1761.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!